
### FOR AUSTRALIAN HEALTHCARE PROFESSIONALS

### **MEETING INVITATION**

## GSK invites you to an educational event **EVOLVING RESPIRATORY MANAGEMENT**



ТІМЕ	AGENDA

### **SPEAKERS**



To register directly with your representative, please contact:

### To register via QR code, please scan:

GSK







# COPD & ASTHMA LEARNING OBJECTIVES

Explore the burden of COPD and ASTHMA in Australia

Focus on the unmet need for patients with COPD and ASTHMA

Understand the role of TRELEGY Ellipta, a single inhaler triple therapy in the management of appropriate COPD and ASTHMA patients<sup>1</sup>

## RSV LEARNING OBJECTIVES

Discuss the burden of RSV disease in older adults

Introduce AREXVY: the only adjuvanted RSV vaccine for older adults<sup>1</sup>

Describe the efficacy and safety of AREXVY

Develop strategies to implement AREXVY into your practice

### TRELEGY Ellipta

PBS Information: **Severe asthma** (200/62.5/25 mcg presentation only); **Chronic obstructive pulmonary disease** (100/62.5/25 mcg presentation only): Authority Required (streamlined). Criteria apply. Refer to PBS for full information.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Product Information can be accessed at www.gsk.com.au/trelegy

Indications<sup>1</sup>: COPD: Maintenance treatment of adults with moderate to severe COPD who require LAMA+LABA+ICS (100/62.5/25 mcg presentation only). Not indicated for initiation in COPD. Asthma: Maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA. Contraindications<sup>1</sup>: Severe milk-protein allergy or hypersensitivity to any of the ingredients. Pregnancy<sup>1</sup>: Category B3. Adverse Effects<sup>1</sup>: Nasopharyngitis, headache, cough, oropharyngeal pain, pneumonia, upper respiratory tract infection, influenza, pharyngitis, dysphonia, rhinitis, arthralgia, back pain, constipation, sinusitis, bronchitis, urinary tract infection, candidiasis of mouth and throat. Dosage<sup>1</sup>: COPD: TRELEGY 100/62.5/25 mcg: One inhalation once daily. After inhalation, rinse mouth with water without swallowing.

#### AREXVY

PBS Information: AREXVY is not listed on the PBS or the National Immunisation Program (NIP).

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Product Information can be accessed at www.gsk.com.au/arexvy

Indication<sup>2</sup>: AREXVY is indicated for active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV). Vaccines may not protect all recipients. **Dosing and administration**<sup>2</sup>: AREXVY is administered as a single, reconstituted dose of 0.5mL by intramuscular injection. The need for revaccination has not been established. **Safety**<sup>2</sup>: Very common adverse events ( $\geq 10\%$ ) are headache, myalgia, arthralgia, injection site pain and fatigue. Common adverse events ( $\geq 10\%$ ) are injection site swelling, fever, chills and rhinorrhoea (not a complete list; see full PI).



Abbreviations: COPD, chronic obstructive pulmonary disease; RSV, respiratory syncytial virus

References: 1. TRELEGY Product Information 2. AREXVY Product Information

This educational activity was initiated, developed and organised by GSK. This is an educational event for your professional development. Therefore, accompanied persons such as family members or friends are not invited to attend.

We GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to send you direct marketing material and to contact you regarding our activities and products or developments in pharmaceutical treatments which may be of interest to you. We may disclose your personal information to third parties we use in the ordinary operations of our business, including our affiliates and third parties located overseas. If we do not collect your personal information, we may be unable to provide you with all our services. Our privacy policy can be found at https://privacy.gsk.com/en-au/privacy-notice/general/ and contains information about how you may access and correct personal information held by us and how you can complain about a breach of privacy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd. PO Box 18095, Melbourne, Victoria, 8003

For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trade marks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481, Melbourne, VIC PM-AU-RSA-LBND-240003 Date of approval: Februrary 2024.



### SCAN OR CODE

to see full TRELEGY Ellipta Product Information



### SCAN QR CODE

to see full AREXVY Product Information



fluticasone furoate/umeclidinium/vilanterol

**I RELEGY** ELLIPTA